Deciphera Pharmaceuticals Inc. closed an underwritten public offering for gross proceeds of $172 million.
The company offered 4,300,000 common shares at $40 apiece.
J.P. Morgan and Piper Jaffray & Co. acted as joint book-running managers for the offering, with Canaccord Genuity LLC and JMP Securities LLC as lead managers. Nomura Securities International Inc. and Raymond James & Associates Inc. acted as co-managers.
Waltham, Mass.-based Deciphera Pharmaceuticals makes treatments for cancer.
